Sebastien J Hazard
Overview
Explore the profile of Sebastien J Hazard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
174
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Del Campo J, Matulonis U, Malander S, Provencher D, Mahner S, Follana P, et al.
J Clin Oncol
. 2019 Jun;
37(32):2968-2973.
PMID: 31173551
Purpose: In the ENGOT-OV16/NOVA trial (ClinicalTrials.gov identifier: NCT01847274), maintenance therapy with niraparib, a poly(ADP-ribose) polymerase inhibitor, prolonged progression-free survival in patients with platinum-sensitive, recurrent ovarian cancer who had a response...
2.
Fabbro M, Moore K, Dorum A, Tinker A, Mahner S, Bover I, et al.
Gynecol Oncol
. 2019 Jan;
152(3):560-567.
PMID: 30638768
Objective: To analyze the safety and efficacy of niraparib in patients aged ≥70 years with recurrent ovarian cancer in the ENGOT-OV16/NOVA trial. Methods: The trial enrolled 2 independent cohorts with...
3.
Lunacsek O, Ravelo A, Coutinho A, Hazard S, Green M, Willey J, et al.
Drugs Real World Outcomes
. 2016 Oct;
3(3):333-343.
PMID: 27747837
Background: Real-world evidence is lacking on the impact of bevacizumab added to carboplatin/paclitaxel (Bev + CP) therapy versus CP alone for patients with non-squamous non-small cell lung cancer (NS-NSCLC), particularly...
4.
Leon L, Kosty M, Jahanzeb M, Spigel D, Wozniak A, Brahmer J, et al.
Pharmacoepidemiol Drug Saf
. 2016 Jan;
25(5):569-77.
PMID: 26748833
Purpose: Bevacizumab used in combination with first-line chemotherapy confers an overall survival (OS) benefit for patients with non-squamous non-small-cell lung cancer (NSCLC). This analysis from the ARIES observational cohort study...
5.
Langer C, Socinski M, Patel J, Sandler A, Schiller J, Leon L, et al.
Am J Clin Oncol
. 2015 Jan;
39(5):441-7.
PMID: 25628268
Background: Patient-level data from 2 phase III studies in patients with previously untreated, advanced-stage, nonsquamous non-small cell lung cancer (NSCLC) were pooled to examine outcomes with bevacizumab and chemotherapy based...
6.
Kosty M, Wozniak A, Jahanzeb M, Leon L, Fish S, Hazard S, et al.
Target Oncol
. 2015 Jan;
10(4):509-16.
PMID: 25559289
Data from randomized, controlled trials suggest that post-induction phase (IP) treatment with bevacizumab may benefit patients with advanced non-small-cell lung cancer (NSCLC). Real-world clinical practice, however, can involve variable use...
7.
Langer C, Ravelo A, Hazard S, Guerin A, Ionescu-Ittu R, Latremouille-Viau D, et al.
Lung Cancer
. 2014 Dec;
86(3):350-7.
PMID: 25439437
Objective: The use of bevacizumab in advanced non-squamous non-small cell lung cancer (NSCLC) is controversial among elderly patients. This study aimed to compare overall survival for Medicare patients diagnosed with...
8.
Lynch Jr T, Spigel D, Brahmer J, Fischbach N, Garst J, Jahanzeb M, et al.
J Thorac Oncol
. 2014 Aug;
9(9):1332-9.
PMID: 25122429
Introduction: Bevacizumab, a recombinant humanized monoclonal antibody against vascular endothelial growth factor, was approved by the US Food and Drug Administration for the treatment of advanced non-small-cell lung cancer (NSCLC)...